據彭博新聞社報道，在諾和諾德肥胖症交易後，禮來放棄了 CVS 為員工提供的藥物計劃

路透中文

2025/11/12

據彭博新聞社報道，在<a href="https://laohu8.com/S/NVO">諾和諾德</a>肥胖症交易後，<a href="https://laohu8.com/S/LLY">禮來</a>放棄了 CVS 為員工提供的藥物計劃

路透11月12日 - 彭博新聞社周二援引知情人士的話報道，禮來LLY.N將放棄CVS HealthCVS.N為其員工提供的藥物福利計劃，因為CVS停止承保其減肥藥，轉而承保諾和諾德NOVOb.CO的一種競爭對手藥物。

彭博社援引他們查看的一份文件稱，從1月1日起，禮來公司醫療計劃覆蓋的員工將自動通過一家名為Rightway的私營藥房福利管理公司加入藥房福利保險。

路透無法立即覈實彭博社的報道。

(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582431706"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582431706\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582431706?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-12 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582431706","market":"us","top_or_hot":-1,"title":"據彭博新聞社報道，在諾和諾德肥胖症交易後，禮來放棄了 CVS 為員工提供的藥物計劃","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>據彭博新聞社報道，在<a href=\"https://laohu8.com/S/NVO\">諾和諾德</a>肥胖症交易後，<a href=\"https://laohu8.com/S/LLY\">禮來</a>放棄了 CVS 為員工提供的藥物計劃</title></head><body><p><span>路透11月12日</span><span> - </span>彭博新聞社周二援引知情人士的話報道，禮來<span>LLY.N</span>將放棄CVS Health<span>CVS.N</span>為其員工提供的藥物福利計劃，因為CVS停止承保其減肥藥，轉而承保諾和諾德<span>NOVOb.CO</span>的一種競爭對手藥物。</p><p>彭博社援引他們查看的一份文件稱，從1月1日起，禮來公司醫療計劃覆蓋的員工將自動通過一家名為Rightway的私營藥房福利管理公司加入藥房福利保險。</p><p>路透無法立即覈實彭博社的報道。</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>據彭博新聞社報道，在諾和諾德肥胖症交易後，禮來放棄了 CVS 為員工提供的藥物計劃</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n據彭博新聞社報道，在諾和諾德肥胖症交易後，禮來放棄了 CVS 為員工提供的藥物計劃\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2025-11-12 10:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>據彭博新聞社報道，在<a href=\"https://laohu8.com/S/NVO\">諾和諾德</a>肥胖症交易後，<a href=\"https://laohu8.com/S/LLY\">禮來</a>放棄了 CVS 為員工提供的藥物計劃</title></head><body><p><span>路透11月12日</span><span> - </span>彭博新聞社周二援引知情人士的話報道，禮來<span>LLY.N</span>將放棄CVS Health<span>CVS.N</span>為其員工提供的藥物福利計劃，因為CVS停止承保其減肥藥，轉而承保諾和諾德<span>NOVOb.CO</span>的一種競爭對手藥物。</p><p>彭博社援引他們查看的一份文件稱，從1月1日起，禮來公司醫療計劃覆蓋的員工將自動通過一家名為Rightway的私營藥房福利管理公司加入藥房福利保險。</p><p>路透無法立即覈實彭博社的報道。</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持倉","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL4S3WO04K:1","article_id":"2582431706","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582431706","pubTimestamp":1762914958,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"據彭博新聞社報道，在諾和諾德肥胖症交易後，禮來放棄了 CVS 為員工提供的藥物計劃路透11月12日 - 彭博新聞社周二援引知情人士的話報道，禮來LLY.N將放棄CVS HealthCVS.N為其員工提供的藥物福利計劃，因為CVS停止承保其減肥藥，轉而承保諾和諾德NOVOb.CO的一種競爭對手藥物。彭博社援引他們查看的一份文件稱，從1月1日起，禮來公司醫療計劃覆蓋的員工將自動通過一家名為Rightway的私營藥房福利管理公司加入藥房福利保險。路透無法立即核實彭博社的報道。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0058720904.USD":"联博国际健康护理基金A","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","BK4550":"红杉资本持仓","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","CVS":"西维斯健康","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LLY":"礼来","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"Eli Lilly drops CVS drug plan for employees after Novo Nordisk obesity deal, Bloomberg News reports","themeId":"57483f769d65fc20ecc128eb009420e1","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":0.9,"LLY":0.9},"content_text":"據彭博新聞社報道，在諾和諾德肥胖症交易後，禮來放棄了 CVS 為員工提供的藥物計劃路透11月12日 - 彭博新聞社周二援引知情人士的話報道，禮來LLY.N將放棄CVS HealthCVS.N為其員工提供的藥物福利計劃，因為CVS停止承保其減肥藥，轉而承保諾和諾德NOVOb.CO的一種競爭對手藥物。彭博社援引他們查看的一份文件稱，從1月1日起，禮來公司醫療計劃覆蓋的員工將自動通過一家名為Rightway的私營藥房福利管理公司加入藥房福利保險。路透無法立即核實彭博社的報道。(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}